Market Research Logo

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016

Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Review, H1 2016’, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted pipeline therapeutics.

The report provides comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)
  • The report reviews Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) Overview
Therapeutics Development
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Stage of Development
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Therapy Area
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Indication
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Companies
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Products under Development by Universities/Institutes
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Companies Involved in Therapeutics Development
Amgen Inc.
AnGes MG, Inc.
Kringle Pharma, Inc.
M3 Biotechnology, Inc.
Minerva Biotechnologies Corporation
Molecular Partners AG
ViroMed Co., Ltd.
Yooyoung Pharmaceutical Co., Ltd.
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Drug Profiles
beperminogene perplasmid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MM-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-0250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilotumumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Dormant Projects
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Discontinued Products
Hepatocyte Growth Factor (Hepatopoietin-A or Lung Fibroblast Derived Mitogen) - Featured News & Press Releases
May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis
Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study
Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma
Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer
Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference
Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer
Aug 12, 2015: Patient Enrollment Begins in Europe in the Global Phase III Clinical Trial of HGF Gene Therapy for Critical Limb Ischemia
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
Nov 24, 2014: Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced Gastric Cancer
Nov 13, 2014: First Patient Dosed in Global Phase III Clinical Trials of HGF Plasmid for Critical Limb Ischemia
Oct 29, 2014: AnGes to Start Global Phase III Clinical Trials of HGF Gene Therapy for Critical Limb Ischemia in Europe
Oct 16, 2014: First Patient Dosed in Physician-led Study of HGF Gene Therapy in Japan
Oct 05, 2014: AnGes Starts Global Phase III Clinical Trials of Collategene for Critical Limb Ischemia
Jun 16, 2014: Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
Jun 12, 2014: AnGes Signs an Agreement with Quintiles for the Global Phase III Trial of Collategene, a Gene Therapy Product for Critical Limb Ischemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Amgen Inc., H1 2016
Pipeline by AnGes MG, Inc., H1 2016
Pipeline by Kringle Pharma, Inc., H1 2016
Pipeline by M3 Biotechnology, Inc., H1 2016
Pipeline by Minerva Biotechnologies Corporation, H1 2016
Pipeline by Molecular Partners AG, H1 2016
Pipeline by ViroMed Co., Ltd., H1 2016
Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report